Orgenesis Announces Strategic Partnership with Harley Street Healthcare Group to Launch a State-of-the-Art Longevity & Wellness Initiative Globally

Core Insights - Orgenesis Inc. has entered a strategic partnership with Harley Street Healthcare Group to enhance the development and commercialization of wellness and longevity therapies aimed at reducing lifestyle-related illnesses [1][5] Partnership Details - A joint venture (JV) will be established, with Orgenesis holding 49% and HSHG holding 51% [2] - The JV will focus on innovative health and wellness services, including personalized preventative care and regenerative therapies, under a "Health-Wellness-as-a-Service" (HWAAS) model [2] Product Launch Plans - The JV plans to introduce a range of wellness and longevity products by the end of 2024, including immune cell banking, aging therapies, preventative illness screening, and stem cell regenerative therapies [3] - Initial rollout will target regions such as the UK, UAE, MENA, Canada, ASEAN, the Balkans, Africa, Latin America, and the Indian subcontinent [3] Investment Commitment - HSHG has committed to invest up to $10 million over three years into Orgenesis and the joint venture [4] Leadership Perspectives - The CEO of Orgenesis highlighted the partnership as a significant milestone in expanding the company's presence in the global wellness market, aiming to redefine patient care and longevity [5] - The Founder of HSHG expressed enthusiasm for the collaboration, emphasizing a shared vision of enhancing health outcomes through innovative therapies [5] Company Background - Orgenesis is a global biotech company focused on unlocking the potential of cell and gene therapies since 2012, with a decentralized approach to processing introduced in 2020 [7] - The company aims to advance its therapies toward commercialization while partnering with industry stakeholders for broader access and better outcomes [7]